Robert A Franklin1, Smith Giri2, Poojitha Valasareddy2, Lindsey T Lands3, Mike G Martin4. 1. College of Medicine, The University of Tennessee Health Science Center, Memphis, TN. Electronic address: rfrankln@gmail.com. 2. College of Medicine, The University of Tennessee Health Science Center, Memphis, TN. 3. Department of Internal Medicine, The University of Tennessee Health Science Center, Memphis, TN; Department of Hematology/Oncology, The West Cancer Center, The University of Tennessee Health Science Center, Memphis, TN. 4. Department of Hematology/Oncology, The West Cancer Center, The University of Tennessee Health Science Center, Memphis, TN.
Abstract
BACKGROUND: Anal adenocarcinoma (AA) represents 5% to 10% of anal cancer. Little is known about its natural history and prognosis. Using population-based data, we defined the outcomes of AA relative to other anorectal malignancies. PATIENTS AND METHODS: We analyzed the Surveillance, Epidemiology, and End Results 18 database to identify patients ≥ 18 years old with AA, squamous cell carcinoma of the anus (SCCA), and rectal adenocarcinoma (RA) diagnosed between 1990 and 2011. Median overall survival (OS), 1-year, 3-year, 5-year, and 10-year OS were computed using actuarial methods. The log rank test was used to estimate the difference between Kaplan-Meier survival curves. A Cox proportional hazard regression model was used to adjust the effects of other covariates on survival, including age, year diagnosed, sex, stage, surgery, and radiation. RESULTS: Of 57,369 cases, 0.8% (n = 462) were patients with AA, 87.8% (n = 50,382) were patients with RA, and 11.4% (n = 6525) were patients with SCCA. The median age for AA was 69 years (range, 20-96 years), 66 years (range, 18-103 years) for RA, and 66 years (range, 14-104 years) for SCCA. The median OS was significantly lower for AA (33 months), compared with SCCA (118 months) and RA (68 months) (P < .01). In multivariate analysis, AA had a worse prognosis compared with SCCA (hazard ratio [HR], 0.66; 95% confidence interval [CI], 0.59-0.75; P < .01) and RA (HR, 0.68; 95% CI, 0.61-0.77; P < .01), after adjusting for age, sex, race, stage, grade, radiation, and surgery. There was a strong trend for improved survival among patients who received radical surgery (HR, 0.71; 95% CI, 0.51-1.00; P = .05). CONCLUSION: AA confers a significantly worse prognosis than SCCA and RA.
BACKGROUND:Anal adenocarcinoma (AA) represents 5% to 10% of anal cancer. Little is known about its natural history and prognosis. Using population-based data, we defined the outcomes of AA relative to other anorectal malignancies. PATIENTS AND METHODS: We analyzed the Surveillance, Epidemiology, and End Results 18 database to identify patients ≥ 18 years old with AA, squamous cell carcinoma of the anus (SCCA), and rectal adenocarcinoma (RA) diagnosed between 1990 and 2011. Median overall survival (OS), 1-year, 3-year, 5-year, and 10-year OS were computed using actuarial methods. The log rank test was used to estimate the difference between Kaplan-Meier survival curves. A Cox proportional hazard regression model was used to adjust the effects of other covariates on survival, including age, year diagnosed, sex, stage, surgery, and radiation. RESULTS: Of 57,369 cases, 0.8% (n = 462) were patients with AA, 87.8% (n = 50,382) were patients with RA, and 11.4% (n = 6525) were patients with SCCA. The median age for AA was 69 years (range, 20-96 years), 66 years (range, 18-103 years) for RA, and 66 years (range, 14-104 years) for SCCA. The median OS was significantly lower for AA (33 months), compared with SCCA (118 months) and RA (68 months) (P < .01). In multivariate analysis, AA had a worse prognosis compared with SCCA (hazard ratio [HR], 0.66; 95% confidence interval [CI], 0.59-0.75; P < .01) and RA (HR, 0.68; 95% CI, 0.61-0.77; P < .01), after adjusting for age, sex, race, stage, grade, radiation, and surgery. There was a strong trend for improved survival among patients who received radical surgery (HR, 0.71; 95% CI, 0.51-1.00; P = .05). CONCLUSION: AA confers a significantly worse prognosis than SCCA and RA.
Authors: Nicholas P McKenna; John R Bergquist; Elizabeth B Habermann; Heidi K Chua; Scott R Kelley; Kellie L Mathis Journal: Int J Colorectal Dis Date: 2019-01-11 Impact factor: 2.571
Authors: Hae Lin Cho; Vedang Murthy; Kent W Mouw; Anthony V D'Amico; Paul L Nguyen; Jonathan E Leeman; Edward Christopher Dee Journal: Prostate Date: 2022-06-02 Impact factor: 4.012
Authors: Lucas Tadeu Bidinotto; Carlos A R Véo; Edgar Aleman Loaiza; Guilherme G Ribeiro; Adriana T Lorenzi; Luciana Albina Reis Rosa; Cristina Mendes De Oliveira; José Eduardo Levi; Cristovam Scapulatempo-Neto; Adhemar Longatto-Filho; Rui Manuel Reis Journal: Oncol Lett Date: 2018-05-30 Impact factor: 2.967
Authors: Max S Chiu; Vivek Verma; Nathan R Bennion; Abhijeet R Bhirud; Jinluan Li; Mary E Charlton; Chandrakanth Are; Chi Lin Journal: Cancer Med Date: 2016-10-26 Impact factor: 4.452
Authors: Rodney E Wegner; Richard J White; Shaakir Hasan; Moses Raj; Dulabh Monga; Gene Finley; Alexander V Kirichenko; James McCormick Journal: Cancer Med Date: 2019-06-07 Impact factor: 4.452